Advertisement

International Journal of Clinical Oncology

, Volume 16, Issue 5, pp 577–580 | Cite as

A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib

  • Kazuyuki Numakura
  • Norihiko Tsuchiya
  • Takeshi Yuasa
  • Mitsuru Saito
  • Takashi Obara
  • Hiroshi Tsuruta
  • Shintaro Narita
  • Yohei Horikawa
  • Shigeru Satoh
  • Tomonori HabuchiEmail author
Case Report

Abstract

We report a case of Xp11.2 translocation renal cell carcinoma (RCC) whose lung metastases were effectively treated with sunitinib. A 43-year-old woman presenting with upper abdominal pain was diagnosed with a left renal tumor. Laparoscopic left radical nephrectomy was performed. Histopathological examination of the surgical specimen revealed a clear-cell carcinoma of the left kidney. Two years later, multiple lung metastases were detected and the patient was treated daily with 50 mg sunitinib. A computed tomography scan performed after 2 cycles of sunitinib treatment revealed partial regression of these metastases. The partial regression has been maintained for >3 years. In retrospective evaluation of the primary RCC, tumor cells showed strong nuclear staining for transcription factor E3 (TFE3) protein and TFE3 split-fluorescence in-situ hybridization revealed translocation involving the TFE3 gene. These findings strongly support diagnosis of Xp11.2 translocation RCC.

Keywords

Renal cell carcinoma Xp11.2 translocation Sunitinib Fluorescence in situ hybridization 

Notes

Conflict of interest

No author has any conflict of interest.

References

  1. 1.
    Argani P, Antonescu CR, Illei PB et al (2001) Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma. Am J Pathol 159:179–192PubMedCrossRefGoogle Scholar
  2. 2.
    Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590PubMedCrossRefGoogle Scholar
  3. 3.
    Winarti NW, Argani P, De Marzo AM et al (2008) Pediatric renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion. Int J Surg Pathol 16:66–72PubMedCrossRefGoogle Scholar
  4. 4.
    Choueiri TK, Mosquera JM, Hirsch MS (2009) A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. Clin Genitourin Cancer 7:93–94CrossRefGoogle Scholar
  5. 5.
    Zhong M, De Angelo P, Osborne L et al (2010) Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma. Am J Surg Pathol 34:757–766PubMedCrossRefGoogle Scholar
  6. 6.
    Tsuda M, Davis IJ, Argani P et al (2007) TEF3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 67:919–929PubMedCrossRefGoogle Scholar
  7. 7.
    Malouf GG, Camparo P, Oudard S et al (2010) Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol 21:1834–1838PubMedCrossRefGoogle Scholar
  8. 8.
    Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337PubMedGoogle Scholar
  9. 9.
    O’Farrell AM, Abrams TJ, Yuen HA et al (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597–3605PubMedCrossRefGoogle Scholar
  10. 10.
    Chow LQM, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884–896PubMedCrossRefGoogle Scholar
  11. 11.
    Stacchiotti S, Tamborini E, Marrari A et al (2009) Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 15:1096–1104PubMedCrossRefGoogle Scholar
  12. 12.
    Ivan M, Bond JA, Prat M et al (1997) Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 14:2417–2423PubMedCrossRefGoogle Scholar
  13. 13.
    Wang SY, Chen B, Zhan YQ et al (2004) SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J Hepatol 41:267–273PubMedCrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2010

Authors and Affiliations

  • Kazuyuki Numakura
    • 1
  • Norihiko Tsuchiya
    • 1
  • Takeshi Yuasa
    • 1
  • Mitsuru Saito
    • 1
  • Takashi Obara
    • 1
  • Hiroshi Tsuruta
    • 1
  • Shintaro Narita
    • 1
  • Yohei Horikawa
    • 1
  • Shigeru Satoh
    • 1
  • Tomonori Habuchi
    • 1
    Email author
  1. 1.Department of UrologyAkita University Graduate School of MedicineAkitaJapan

Personalised recommendations